Algernon closes $177,000 first tranche of financing

Executive Summary

• Algernon Health Inc. has closed the first tranche of its non-brokered private placement financing.
• The company raised gross proceeds of $177,000 from the sale of 2,528,752 units.
• Proceeds will be used to advance the Alzheimer's disease program, including opening the first U.S. AD clinic, and for general and administrative expenses.

Key Details

• Transaction Structure: Non-brokered private placement.
• Gross Proceeds: $177,000.
• Units Sold: 2,528,752 units.
• Issue Price: $0.07 per unit.
• Insider Participation: Insiders participated in the amount of $37,000. This constitutes a related party transaction under Multilateral Instrument 61-101. The company relied on exemptions from valuation and minority shareholder approval requirements as the insider purchase did not exceed 25% of market capitalization.
• Finders' Fees: No cash finders' fees were paid.
• Use of Proceeds: Advancing the Alzheimer's disease (AD) program (including opening the first U.S. AD clinic), general and administrative expenses, and working capital.
• Future Tranches: Additional tranches are expected to close on or before December 1, 2025.
• Securities Restrictions: Securities are subject to a statutory hold period of four months plus one day from the date of issuance.

Notable Quotes

• None provided in the text.